Nivalis Therapeutics, Inc.
(NASDAQ : NVLS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading NVLS News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.09%70.411.0%$912.98m
AMGNAmgen Inc.
1.48%179.150.8%$648.77m
BIIBBiogen Inc.
1.57%293.140.9%$502.27m
CELGCelgene Corporation
0.55%124.191.0%$500.79m
INCYIncyte Corporation
1.36%134.912.3%$450.57m
REGNRegeneron Pharmaceuticals, Inc.
1.43%378.831.9%$338.88m
ALXNAlexion Pharmaceuticals, Inc.
1.40%133.092.0%$303.48m
TSROTESARO, Inc.
-3.94%180.9515.3%$161.39m
ILMNIllumina, Inc.
1.03%169.133.9%$158.61m
EXELExelixis, Inc.
3.90%22.375.5%$140.76m
VRTXVertex Pharmaceuticals Incorporated
0.33%90.922.6%$140.24m
CLVSClovis Oncology, Inc.
3.00%59.5516.4%$119.41m
BMRNBioMarin Pharmaceutical Inc.
0.44%94.343.9%$109.20m
AAgilent Technologies, Inc.
1.21%51.921.7%$107.75m
ACADACADIA Pharmaceuticals Inc.
-3.02%36.9619.0%$94.18m

Company Profile

Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO.